Microphyt is a French biotech company that develops, produces and markets microalgae-based natural ingredients.
Thanks to a production process that is unique in the market, Microphyt draws on the exceptional potential of microalgae to provide natural, effective and sustainable solutions for the dietary supplement and cosmetic industries. Microphyt currently employs 20 people and has filed 5 different patent families.
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.